Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pharmacologic mechanisms of crystal meth.

ABSTRACT: Crystal meth is a form of the stimulant drug methamphetamine that, when smoked, can rapidly achieve high concentrations in the brain. Methamphetamine causes the release of the neurotransmitters dopamine, norepinephrine and serotonin and activates the cardiovascular and central nervous systems. The levels of dopamine are low in the brain of some drug users, but whether this represents neuronal loss is uncertain. The areas of the brain involved in methamphetamine addiction are unknown but probably include the dopamine-rich striatum and regions that interact with the striatum. There is no medication approved for the treatment of relapses of methamphetamine addiction; however, potential therapeutic agents targeted to dopamine and nondopamine (e.g., opioid) systems are in clinical testing.

SUBMITTER: Kish SJ

PROVIDER: S-EPMC2413312 | biostudies-literature | 2008 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Pharmacologic mechanisms of crystal meth.

Kish Stephen J SJ

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20080601 13

Crystal meth is a form of the stimulant drug methamphetamine that, when smoked, can rapidly achieve high concentrations in the brain. Methamphetamine causes the release of the neurotransmitters dopamine, norepinephrine and serotonin and activates the cardiovascular and central nervous systems. The levels of dopamine are low in the brain of some drug users, but whether this represents neuronal loss is uncertain. The areas of the brain involved in methamphetamine addiction are unknown but probably ...[more]

PMID: 18559805

Similar Datasets

Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.

Project description:Severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) is an emerging pathogen, which is similar to previous SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) occurrences. However, we only get few understandings about the pathogenesis of SARS-CoV-2, which need to further be studied. The discovery of an agent that has a treatment efficacy against SARS-CoV-2 is very urgent. In this review, we briefly discuss the virology of this pathogen and focus on the available understanding of the pathogenesis and treatments of this pathogen including the uses of nucleoside analogues, protease inhibitors, interferons, and other small-molecule drugs, on the basis previous comprehensions of SARS and MERS. These reviewed concepts may be beneficial in providing new insights and potential treatments for COVID-19.

| S-EPMC7982566 | biostudies-literature

Crystal structure of 2-chloro-3-(di-meth-oxy-meth-yl)-6-meth-oxy-quinoline.

Project description:The title compound, C13H14ClNO3, crystallizes with Z' = 2 in the space group Pca21, but a search for possible additional crystallographic symmetry found none. However, the crystal structure exhibits pseudosymmetry as the two independent mol-ecules are related by an approximate but non-crystallographic inversion located close to (0.38, 0.26, 1/2) in the selected asymmetric unit, and the structure exhibits partial inversion twinning. The approximate inversion relationship between the two mol-ecules in the selected asymmetric unit is clearly shown by comparison of the relevant torsion angle in the two mol-ecules; the corresponding torsion angles have similar, although not identical magnitudes but with opposite signs. The mean planes of the quinoline rings in the two independent mol-ecules are almost parallel, with a dihedral angle of only 0.16?(3)° between them, and the mutual orientation of these rings permits significant ?-? stacking inter-actions between them [centroid-centroid distances = 3.7579?(15) and 3.7923?(15)?Å]. In addition, the bimolecular aggregates which are related by translation along [010] are linked by a further ?-? stacking inter-action [centroid-centroid distance = 3.7898?(15)?Å], so forming a ?-stacked chain running parallel to [010]. However, there are no C-H?N hydrogen bonds in the structure nor, despite the number of independent aromatic rings, are there any C-H?? hydrogen bonds; hence there are no direction-specific inter-actions between adjacent ?-stacked chains.

| S-EPMC4420130 | biostudies-literature

Mechanisms associated with post-stroke depression and pharmacologic therapy.

Project description:Stroke is one of the most common cerebrovascular diseases, which is the cause of long-term mental illness and physical disability, Post-stroke depression (PSD) is the most common neuropsychiatric complication after stroke, and its mechanisms are characterized by complexity, plurality, and diversity, which seriously affects the quality of survival and prognosis of patients. Studies have focused on and recognized neurotransmitter-based mechanisms and selective serotonin-reuptake inhibitors (SSRIs) can be used to treat PSD. Neuroinflammation, neuroendocrinology, neurotrophic factors, and the site of the stroke lesion may affect neurotransmitters. Thus the mechanisms of PSD have been increasingly studied. Pharmacological treatment mainly includes SSRIs, noradrenergic and specific serotonergic antidepressant (NaSSA), anti-inflammatory drugs, vitamin D, ect, which have been confirmed to have better efficacy by clinical studies. Currently, there is an increasing number of studies related to the mechanisms of PSD. However, the mechanisms and pharmacologic treatment of PSD is still unclear. In the future, in-depth research on the mechanisms and treatment of PSD is needed to provide a reference for the prevention and treatment of clinical PSD.

| S-EPMC10651767 | biostudies-literature

Crystal structure of 4-meth-oxy-quinazoline.

Project description:The title compound, C9H8N2O, is almost planar, with the C atom of the meth-oxy group deviating from the mean plane of the quinazoline ring system (r.m.s. deviation = 0.011?Å) by 0.068?(4)?Å. In the crystal, mol-ecules form ?-? stacks parallel to the b-axis direction [centroid-centroid separation = 3.5140?(18)?Å], leading to a herringbone packing arrangement.

| S-EPMC4257374 | biostudies-literature

Crystal structure of 1-meth-oxy-pyrene.

Project description:The title compound, C17H12O, crystallized with three independent mol-ecules (A, B and C) in the asymmetric unit. In the crystal, the three independent mol-ecules are linked by π-π inter-actions [centroid-centroid distances = 3.551 (3)-3.977 (2) Å], which lead to the formation of trimers. Between the trimers there are a number of C-H⋯π inter-actions generating a laminar arrangement parallel to (010). The meth-oxy-methyl group in mol-ecule A is disordered over two sets of sites, with an occupancy ratio of 0.56 (9):0.44 (9).

| S-EPMC4350705 | biostudies-literature

Crystal structure of triphenylphosphonium-meth-yl-enetrifluoroborate.

Project description:The title compound, C19H17BF3P {alternative name: triphen-yl[(tri-fluoro-boran-yl)meth-yl]phosphanium}, was formed by the reaction of tri-phenyl-phosphine with potassium iodo-methyl-tri-fluoro-borate. The mol-ecule features a nearly staggered conformation along the P-C bond and a less than staggered conformation along the C-B bond. In the crystal, weak C-H⋯F hydrogen bonds between the meta-phenyl C-H groups and the tri-fluoro-borate B-F groups form chains of R22(16) rings along [100]. These chains are are further stabilized by weak C-H⋯π inter-actions. A weak intra-molecular C-H⋯F hydrogen bond is also observed.

| S-EPMC5598835 | biostudies-literature

Crystal structure of 3,4-di-meth-oxy-phenol.

Project description:The title compound, C8H10O3, has two planar mol-ecules in the asymmetric unit possessing mean deviations from planarity of 0.051 and 0.071 Å. In the crystal, there are two distinct infinite chains, both along [010]. The chains are formed by O-H⋯O inter-actions between the phenol and both the 3-meth-oxy and the 4-meth-oxy groups.

| S-EPMC4719955 | biostudies-literature

Crystal structure of 3-(hy-droxy-meth-yl)chromone.

Project description:In the title compound, C10H8O3 (systematic name 3-hy-droxy-methyl-4H-chromen-4-one), the fused-ring system is slightly puckered [dihedral angle between the rings = 3.84 (11)°]. The hy-droxy O atom deviates from the heterocyclic ring by 1.422 (1) Å. In the crystal, inversion dimers linked by pairs of O-H⋯O hydrogen bonds generate R 2 (2)(12) loops. The dimers are linked by aromatic π-π stacking [shortest centroid-centroid distance = 3.580 (3) Å], and C-H⋯O hydrogen bonds, generating a three-dimensional network.

| S-EPMC4518918 | biostudies-literature

Crystal structure of 2-meth-oxy-1-nitro-naphthalene.

Project description:The asymmetric unit of the title compound, C11H9NO3, contains two mol-ecules, A and B. In mol-ecule A, the dihedral angle between the planes of the naphthalene ring system (r.m.s. deviation = 0.003 Å) and the nitro group is 89.9 (2)°, and the C atom of the meth-oxy group deviates from the naphthyl plane by 0.022 (2) Å. Equivalent data for mol-ecule B are 0.008 Å, 65.9 (2)° and -0.198 (2) Å, respectively. In the crystal, mol-ecules are linked by weak C-H⋯O inter-actions, forming [100] chains of alternating A and B mol-ecules. Weak aromatic π-π stacking contacts, with a range of centroid-centroid distances from 3.5863 (9) to 3.8048 (9) Å, are also observed.

| S-EPMC4647346 | biostudies-literature

Crystal structure of bis-(4-meth-oxy-phenyl) malonate.

Project description:The complete mol-ecule of the title compound, C17H16O6, is generated by crystallographic twofold symmetry, with the central methyl-ene C atom lying on the rotation axis. The carbonyl O atom is disordered over two adjacent positions in a 0.63 (3):0.37 (3) ratio and the dihedral angle between the benzene rings in the two halves of the mol-ecule is 79.31 (12)°. In the crystal, mol-ecules are connected by C-H⋯O hydrogen bonds, generating (110) sheets. Very weak intra-sheet C-H⋯π inter-actions are also observed.

| S-EPMC4420049 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data